Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (514)	3/29/2001 1:15:24 PM
From: tuck	Respond to of 1784

PCOP, one of the few Trickle holdings that sports a realistic PEG ratio, scores another win: >>Pharmacopeia Announces New Collaboration With Mitsubishi-Tokyo Pharmaceuticals PRINCETON, N.J., March 29 /PRNewswire/ -- Pharmacopeia, Inc. (Nasdaq: PCOP - news) today announced that it has signed a new collaboration agreement with Mitsubishi-Tokyo Pharmaceuticals, a company involved in the discovery, development, and commercialization of pharmaceutical products, and a wholly-owned subsidiary of Mitsubishi Chemical Corporation. Under the terms of this new agreement, Pharmacopeia will utilize its assay development expertise, its proprietary, multimillion compound sample collection, and ultra high throughput screening technology to identify active compounds against a Mitsubishi-Tokyo target. Pharmacopeia will receive fees for providing these services and will receive additional payments upon the successful achievement of milestones. Pharmacopeia will also be entitled to royalties on marketed products that may result from this agreement. ``Utilizing the unique combination of our multi-million compound sample collection of novel small molecules and ultra high-throughput screening, we will seek to augment Mitsubishi-Tokyo's internal discovery efforts by identifying potent initial lead compounds on their behalf,'' said Joseph A. Mollica, Ph.D. Chairman, President and CEO of Pharmacopeia. ``Given our historical success in identifying such compounds against biologically challenging targets, we look forward to a long and successful relationship with our new partner.''<< Trickle had been tempted to get more PCOP, and had it hit, say 15, while I was watching, it would have. But I've been spending some cash lately, and I'm running low on what I want spend here. I want to reserve some for investments in new trickle companies such as XGEN, MIL, APBI, etc., and perhaps to double up on high flyers like IVGN should they fall further. I expect to hold most of these companies for a while, so raising cash through selling a component of the portfolio won't be an option for some time. Cheers, Tuck